This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioCardia’s 8K filing here.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Featured Articles
- Five stocks we like better than BioCardia
- Best Stocks Under $5.00
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
- What Are the FAANG Stocks and Are They Good Investments?
- Vistra Corp: A Winning Bet on the Future of Renewable Energy
- What Does Downgrade Mean in Investing?
- New Highs for Dow Transports: Top 3 Stocks Driving the Surge
